Le Lézard
Classified in: Health
Subjects: CCA, FVT

­Nevro to Report Second Quarter 2019 Financial Results


REDWOOD CITY, Calif., July 15, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the second quarter ended June 30, 2019 after the market closes on August 8, 2019.

Investors interested in listening to the conference call may do so by dialing (833) 286-5807 in the U.S. or (647) 689-4452 internationally, using Conference ID: 1694716.  In addition, a live webcast, as well as an archived recording, will be available on the "Investors" section of the Company's website at: www.nevro.com.

About Nevro Corp. 
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The Senza® System and Senza IItm System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

Investor Relations:
Juliet Cunningham
Vice President, Investor Relations
650-433-3247
[email protected]

.

 

SOURCE Nevro Corp.


These press releases may also interest you

at 10:35
BeiGene, Ltd. , a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company's strategy, the progress it has made towards existing goals, and how it intends to achieve its bold new targets. This...

at 10:30
Invensify, Inc., Santa Clara, California, has introduced a power efficient, temperature-controlled shipping container designed to maintain stable storage temperatures for high-value pharmaceuticals before and during transport to last-mile cold chain...

at 10:30
Oligonucleotide Synthesis Market in terms of revenue was estimated to be worth $8.8 billion in 2024 and is poised to reach $19.7 billion by 2029, growing at a CAGR of 17.5% from 2024 to 2029 according to a new report by MarketsandMarketstm. One of...

at 10:30
Efforts are underway to reach more people with suicide prevention information and interventions across Illinois during Mental Health Awareness Month in May. The Illinois chapter of the American Foundation for Suicide Prevention (AFSP) is hosting...

at 10:00
Iris Wellness Group has introduced an Outpatient Drug and Alcohol Detox Program in Chattanooga, TN, offering personalized care for individuals grappling with addiction. Launched on April 15th, 2024, this unique detox program allows patients to...

at 10:00
CREO Inc., the preferred consultancy to the world's most promising companies that seek to improve human health, today announced that Mike Townley, President and Co-Founder, has been honored with...



News published on and distributed by: